Amgen — Apr 30, 2026 release

Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance for the Year Ending December 31, 2026 (Unaudited) GAAP diluted EPS guidance $ 15.62  — $ 17.10  Known adjustments to arrive at non-GAAP*: Acquisition-related expenses (a) 6.02  — 6.10  Net losses from equity investments 0.15 Other (0.17) Non-GAAP diluted EPS guidance $ 21.70  — $ 23.10  * The known adjustments are presented net of their related tax impact, which amount to approximately $1.09 per share. (a) The adjustment primarily includes noncash amortization of intangible assets and fair value step-up of inventory acquired in business combinations. Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation, changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments. Reconciliation of GAAP Tax Rate Guidance to Non-GAAP Tax Rate Guidance for the Year Ending December 31, 2026 (Unaudited) GAAP tax rate guidance 14.5  % — 16.0  % Tax rate of known adjustments discussed above 0.5 % Non-GAAP tax rate guidance 15.0  % — 16.5  %